Every hair-loss treatment for women, graded by what was tested in women

Women with thinning hair are offered eight different things, and the order they are offered in has almost nothing to do with the evidence behind them. This page puts the same eight side by side and grades each one on a single question: what has been tested in women, rather than in men or in a questionnaire. The strongest-graded route is also the cheapest, and it earns this site nothing.

Before any of it: hair loss in women is several conditions that look alike at the part. Getting the right name for yours changes the answer completely, and no product on this page can do that for you.

Before treatment, a name for the problem

Get a diagnosis first. This pays nobody — not your pharmacist, not the sites selling subscriptions, and not us — and it is the step that decides whether anything else on this page is relevant.

The American Academy of Dermatology describes what that appointment looks like: a dermatologist asks how long the loss has been going on and whether it came on quickly, looks closely at the scalp and nails, uses a gentle hair-pull test to see how the hair is growing, and orders a blood test or a scalp biopsy if a disease, a deficiency, a hormone problem or an infection might be behind it. Its page on female pattern hair loss, last updated 13 December 2022, is blunt about the reason: dermatologists are the people who can tell pattern loss apart from everything else that mimics it.

Everything that follows assumes that step has happened, or is about to.

Every route a woman is offered, side by side

The grades below are this site's own, and the rule behind them is simple: a randomised, placebo-controlled trial in women outranks a trial in men, which outranks a case series, which outranks a questionnaire the seller commissioned. Nothing here was tested by us — this site treats nobody and measures nothing.

The picture below is the same table, sorted by grade. It is drawn from those cells, so the two cannot drift apart.

The one thing approved over the counter for women

Topical minoxidil is the only active ingredient the FDA has approved over the counter for female pattern hair loss, and the trials behind it were run in women. In a 48-week randomised, placebo-controlled, multicentre trial of 381 women aged 18 to 49, 5% topical minoxidil beat placebo on all three primary measures — non-vellus hair count and both the patient's and the investigator's assessment of growth and scalp coverage. The 2% solution beat placebo on hair count and the investigator's assessment, but not on what the women themselves reported. The same trial found more itching, local irritation and unwanted hair growth with 5% than with 2%.

A separate 24-week randomised trial in 113 women found once-daily 5% foam non-inferior to twice-daily 2% solution, with significantly less itching and dandruff — which matters, because the side effect women actually stop over is usually the scalp, not the science.

What this site will not do is tell you how much to use or how often. That is what the label and a clinician are for. What the label does say, in the version of the women's 5% foam label published on DailyMed and updated 13 November 2024, is that it is not to be used if your hair loss is sudden or patchy, if it followed childbirth, if there is no family history, if you are under 18, or if your scalp is red, inflamed, infected or painful; that it may be harmful if used when pregnant or breastfeeding; and that you should stop and ask a doctor if you get chest pain, a rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, swollen hands or feet, or unwanted facial hair.

Everything else about minoxidil for women — what the shedding phase is, what happens when you stop, and why the same molecule costs wildly different amounts — has its own page.

The prescriptions a doctor may raise, and why they are off-label

Three prescription routes come up in women's hair loss, and all three are off-label, meaning a prescriber is using a medicine approved for something else because they judge it appropriate for you. That decision is theirs and yours; this site has no part in it and prints no doses.

Spironolactone is an anti-androgen the AAD describes as a common treatment for female pattern hair loss. A 2023 systematic review and meta-analysis of the published studies reported improvement in 56.6% of patients overall — 65.8% where it was combined with another treatment, 43.2% on its own — and no improvement or only modest improvement in 37.8%. The adverse effects reported in at least two studies were scalp itching or scurf (18.9%), menstrual disturbance (11.9%) and facial hair growth (6.9%), with 2.8% stopping the drug. The 2023 international PCOS guideline adds the non-negotiable part: anyone taking an anti-androgen who could become pregnant should be counselled to use effective contraception, because of the risk to a male fetus.

Low-dose oral minoxidil is a blood-pressure medicine used off-label. In January 2025 a panel of 43 hair-loss specialists from 12 countries published an international consensus statement in JAMA Dermatology on prescribing it — 76 items agreed, covering which diagnoses it may help, when it is preferred to the topical form, contraindications, baseline evaluation and monitoring. The authors say plainly that larger trials and standardised guidelines are lacking and that long-term safety is one of the critical topics still to be investigated. A consensus of experts is a real thing; it is not the same thing as a trial. What that means for women specifically is a separate piece.

Finasteride and dutasteride are the weakest fit of the three for women, and the evidence is where you would least expect to find it — in the manufacturer's own label. Propecia is indicated for male pattern hair loss "in MEN ONLY". Its label reports a 12-month study of 137 postmenopausal women in which effectiveness could not be demonstrated on any measured outcome against placebo. Finasteride is contraindicated in women who are or may become pregnant, and the label tells women not to handle crushed or broken tablets in that situation because of the risk to a male fetus. The full picture for women, including why some dermatologists still prescribe it, is worth reading before the appointment rather than after it.

Devices, supplements and serums: where the evidence thins

Below the prescriptions, the grades fall away quickly, and the marketing gets louder in exact proportion.

Laser and red-light devices. Home laser devices are FDA-cleared, not FDA-approved: clearance means a device was shown to be substantially equivalent to something already on the market, not that a regulator judged it effective for you. Theradome describes itself as the first FDA-cleared Class II laser phototherapy hair-growth device for home use and cites a 26-week multicentre randomised double-blind trial in which total hair count rose by an average of 10.4 hairs against an average loss of 14.0 hairs in the sham group; it lists the PRO LH80 at $995, marked down from $1,428.99, with a one-year warranty. Those are the maker's figures, quoted as the maker's figures. If you want the device route, Theradome's own page is where its claims live.

Supplements. The best-evidenced brand aimed at women is Nutrafol, whose women's formulas are $88 bought one month at a time or $79 on the monthly plan, and there are randomised placebo-controlled trials in women behind them — funded by the company and co-authored by its own people. That is the whole difficulty in one sentence, and it is why we give supplements a low grade rather than no grade. Our evidence-graded review of the Nutrafol women's range scores it 6 out of 10 on a published scale and shows the arithmetic. Their own product pages carry the current prices and the label.

Serums and shampoos. Drug-free serums make no approved hair-loss claim, and the percentages on their pages are usually consumer perception studies rather than trials — Vegamour's GRO Hair Serum, $64 one-time or $49 on subscription, attributes "93% saw less shedding" to a 120-day perception study of 40 participants. Scandinavian Biolabs prices its women's serum at €65 one-time or €55 on subscription and markets it as drug-free. Both are cosmetics doing cosmetic work, which is a fair thing to buy as long as nobody has told you it is a treatment. Their pages: Vegamour, Scandinavian Biolabs.

Surgery is a minority option, and it needs a donor area

Hair transplant surgery is overwhelmingly performed on men. In the ISHRS 2025 Practice Census, covering 2024, 84.7% of surgical hair-restoration procedures reported by members were performed on men and 15.3% on women; for non-surgical procedures the split was 61.7% and 38.3%. Among women's procedures, 21% targeted areas other than the scalp, eyebrows most commonly.

The reason is not that surgeons dislike operating on women. It is that moving hair requires a donor area that is not itself thinning, and female pattern hair loss is often diffuse — the back and sides thin too. A surgeon who does not raise that with you is not being careful. What women are actually assessed for covers the questions worth asking, and the risks — infection, poor growth, shock loss, over-harvesting, scarring — that belong in the same conversation.

What we will not do on this page

No before-and-after photographs, ever. No "9 in 10 women" figures we did not source. No clinic rankings, no surgeons named, no invented patient quotes, and no dosing of any kind — not for minoxidil, not for anything a prescriber controls.

Where a route is unproven, the grade says so and the page still describes it, because women are being sold it either way and deserve to read the weakness before the sales page tells them the strength. And where the honest answer is a pharmacy generic or an appointment, it is named first and marked as paying us nothing.